Latest News:
28.06.2010
PASylation wins 1st price in the Science4Life Business Plan Contest 2010
17.09.2009
XL-protein GmbH and Bayerische Patent Allianz GmbH have signed an exclusive licensing agreement.
News
September 17, 2009- The Bavarian Patent Alliance GmbH and the biotech company XL-protein GmbH have signed an exclusive licensing agreement on a promising invention of the Technische Universität München.
With the so-called "PASylation-technology", the plasma half-life of biological agents is extended by many times. Therapeutic proteins are directly fused directly fused on the genetic level with sequences from the amino acids proline, alanine and serine. The PAS-polymers named after the initials of these amino acids are stable in plasma and pharmacologically inert. They adopt a bulky random coil structure, which significantly increases the size of the protein. The typically rapid clearance of the active substance via kidney filtration is by this means retarded by 1-2 orders of magnitude. In this way the duration of drug action in the human body can be extended to several days.
Through the acquisition of the worldwide patent rights XL-protein takes, as the exclusive licensee, advantage of the PASylation-technology originally developed at the Insitute of Biological Chemistry at the Technische Universität München (TUM).
